Comparative pharmacokinetics of marbofloxacin in healthy and Mannheimia haemolytica infected calves.
The pharmacokinetics of marbofloxacin were investigated in healthy (n=8) and Mannheimia haemolytica naturally infected (n=8) Simmental ruminant calves following intravenous (i.v.) and intramuscular (i.m.) administration of 2 mg kg(-1) body weight. The concentration of marbofloxacin in plasma was measured using high performance liquid chromatography with ultraviolet detection. Following i.v. administration of the drug, the elimination half-life (t(1/2 beta)) and mean residence time (MRT) were significantly longer in diseased calves (8.2h; 11.13 h) than in healthy ones (4.6 h; 6.1 h), respectively. The value of total body clearance (CL(B)) was larger in healthy calves (3 ml min(-1) kg(-1)) than in diseased ones (1.3 ml min(-1) kg(-1)). After single intramuscular (i.m.) administration of the drug, the elimination half-life, mean residence time (MRT) and maximum plasma concentration (C(max)) were higher in diseased calves (8.0, 12 h, 2.32 microg ml(-1)) than in healthy ones (4.7, 7.4 h, 1.4 microg ml(-1)), respectively. The plasma concentrations and AUC following administration of the drug by both routes were significantly higher in diseased calves than in healthy ones. Protein binding of Marbofloxacin was not significantly different in healthy and diseased calves. The mean value for MIC of marbofloxacin for M. haemolytica was 0.1+/-0.06 microg ml(-1). The C(max)/MIC and AUC(24)/MIC ratios were significantly higher in diseased calves (13.0-64.4 and 125-618 h) than in healthy calves (8-38.33 and 66.34-328 h). The obtained results for surrogate markers of antimicrobial activity (C(max)/MIC, AUC/MIC and T > or = MIC) indicate the excellent pharmacodynamic characteristics of the drug in diseased calves with M. haemolytica, which can be expected to optimize the clinical efficacy and minimize the development of resistance.
Ismail
M
M
Department of Pharmacology, Cairo University, Giza 12211, Egypt. m_ism@hotmail.com
El-Kattan
Y A
YA
D000818:Animals; D019540:Area Under Curve; D016022:Case-Control Studies; D002417:Cattle; D004791:Enzyme Inhibitors / Q000097:blood / Q000493:pharmacokinetics*; D024841:Fluoroquinolones / Q000097:blood / Q000493:pharmacokinetics*; D006262:Health; D016978:Mannheimia haemolytica / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D016871:Pasteurellaceae Infections / Q000097:blood / Q000662:veterinary*; D015363:Quinolones / Q000097:blood / Q000493:pharmacokinetics*
D004791:Enzyme Inhibitors; D024841:Fluoroquinolones; D015363:Quinolones; C080260:marbofloxacin